Skip to content

Clinical Trial of Wrist Ambulatory Blood Pressure Monitor in Conformance With the EN ISO 81060-2:2018+AMD1:2020

Clinical Trial on the Effectiveness and Safety of Blood Pressure Function System of Wrist Ambulatory Blood Pressure Monitor

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06573216
Enrollment
128
Registered
2024-08-27
Start date
2024-04-24
Completion date
2024-06-04
Last updated
2024-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Pressure

Brief summary

The accuracy and safety of the Wrist Ambulatory Blood Pressure Recorder (Model: LCA-B10) were assessed according to the requirements of EN ISO 81060-2:2018 + AMD1:2020.

Interventions

DEVICEWrist Ambulatory Blood Pressure Monitor

Comparing blood pressure measured by wrist blood pressure monitor with mercury sphygmomanometer .

Sponsors

Huawei Device Co., Ltd
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Subjects should voluntarily participate in the clinical trial and sign the informed consent form; 2. Subjects must be willing and able to follow the study procedures; 3. Subjects are over 18 years old whose wrist circumference should be within 13.0-21.0cm.

Exclusion criteria

1. Subjects with serious arrhythmias (atrial fibrillation, atrial flutter, ventricular flutter, ventricular fibrillation, ventricular tachycardia, borderline tachycardia, sinus arrest, pathological sinus syndrome, pacemaker rhythm) showed by electrocardiogram during screening period; 2. Subjects with sickle cell disease; 3. Subjects with prior mastectomy or arm lymph node dissection; 4. Subjects who are allergic to nylon, fluororubber or thermo-plastic polyurethane elastomer (TPU); 5. Subjects with wounds on the limb at the measurement site or inflammation of the wrist 6. Subjects who are undergoing intravenous fluid therapy, blood transfusion or other catheterization at the measurement site limb; 7. Subjects who have eaten, consumed alcohol, smoked cigarettes, or exercised vigorously 30 minutes prior to the trial; 8. Subjects who have participated in other clinical trials within 30 days that may affect this trial; 9. Subjects who, in the opinion of the investigator, should not participate in this clinical trial.

Design outcomes

Primary

MeasureTime frameDescription
Blood pressure mean deviation and standard deviation- evaluation criterion 130 minutesThe mean deviation and standard deviation between the blood pressure values measured by the investigational device and those obtained using the auscultatory method with the reference device. This calculation is performed on valid data pairsof subjects (n≥255). Evaluation criterion 1: The blood pressure mean deviation should not exceed ±5mmHg, and the standard deviation should not exceed 8mmHg.
Blood pressure mean deviation and standard deviation- evaluation criterion 230 minutesThe mean deviation and standard deviation between the blood pressure values measured by the investigational device and those obtained using the auscultatory method with the reference device. This calculation is performed on the valid data group of all subjects (m≥85). Evaluation criterion 2: The blood pressure standard deviation within the valid data group (m ≥ 85) should not exceed the maximum allowable standard deviation corresponding to the mean deviation listed in Criterion 2 in section 5.2.4.1.2 b of ISO 81060-2:2018+AMD1:2020.
The mean deviation and standard deviation of blood pressure measurements under ambulatory blood pressure monitoring30 minutesThe mean deviation and standard deviation of the blood pressure within the valid data group are calculated to evaluate whether the clinical accuracy of the investigational device meets the requirements outlined in ISO 81060-2:2018+AMD1:2020, specifically in section 5.2.4.1.2a). The blood pressure mean deviation should not exceed ±5mmHg, and the standard deviation should not exceed 8mmHg.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026